US/UK/Canada

Share

Pick a time period -
Tags ( Active)

AstraZeneca granted coordination of Prilosec US patent cases

® ASTRAZENECA GRANTED COORDINATION OF PRILOSEC US PATENT CASES AstraZeneca today announced that the Judicial Panel on Multidistrict Litigation has ordered that all pending patent infringement cases in the United States relating to omeprazole should be coordinated for pretrial proceedings in the District Court of Southern District of New York. AstraZeneca filed its motion before the Panel in May 1999, requesting coordination of the pretrial proceedings of the patent actions in New York. There are presently patent infringement cases pending against Andrx Pharmaceuticals, Inc., Genpharm, Inc.,

Astrazeneca - interlocutory injunction in Germany to prevent marketing of a generic omeprazole product upheld

ASTRAZENECA - INTERLOCUTORY INJUNCTION IN GERMANY TO PREVENT MARKETING OF A GENERIC OMEPRAZOLE PRODUCT UPHELD AstraZeneca today announced that an Appeal Court has upheld a previously granted interlocutory injunction in Germany based on AstraZeneca's formulation patents. The injunction prevents Ratiopharm GmbH and Merckle GmbH from marketing a generic omeprazole product. Omeprazole is the substance used in ® Losec . "The Appeal Court's decision supports AstraZeneca's view that the generic industry uses AstraZeneca's patented technology. We are convinced that many more companies market this

Half Year Report AstraZeneca

AstraZeneca PLC Half Year Results 1999 'Strong sales and profits growth in Healthcare' Financial Highlights § Statutory Pro Forma Basis Basis st st st 1 Half 1 Half 1 Half Constant 1999 1999 1998 Currency $m $m $m % % Sales: Group 9,043 9,043 8,096 + 12 + 12 Healthcare 7,382 7,382 6,360 + 16 + 16 Operating Profit: Group 2,103 2,091 1,938 + 8 + 9 Healthcare 1,834 1,822 1,610 + 13 + 13 Profit before Tax 2,092 2,059 1,934 + 6 + 7 Earnings per Share $0.83 $0.81 $0.75 + 8 n/a All narrative in this report refers to pro forma growth rates. Tom McKillop, Chief Executive, said: "AstraZeneca has made

Astrazeneca wins interlocutory* injunction in germany to prevent marketing of a generic version of omeprazole

ASTRAZENECA WINS INTERLOCUTORY* INJUNCTION IN GERMANY TO PREVENT MARKETING OF A GENERIC VERSION OF OMEPRAZOLE AstraZeneca today announced that it has been granted an interlocutory injunction in Germany based on the formulation patents to prevent Ratiopharm GmbH and Merckle GmbH from marketing a generic omeprazole product. Omeprazole ® is the substance used in Losec . "This clearly shows AstraZeneca's determination and resolve when it comes to asserting our patent rights," says Dr. Martin Nicklasson, Executive Vice President GI Franchise. "The granting of the interlocutory injunction

AstraZeneca completes sale of Zeneca specialities

ASTRAZENECA COMPLETES SALE OF ZENECA SPECIALITIES AstraZeneca today completed the previously announced sale of its Zeneca Specialities business for a cash amount of $2.1 billion (£1.3) in a buyout jointly financed by Cinven and Investcorp. Further enquiries: Media: Steve Brown, Media Relations Manager, tel +44 171 304 5033 ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/06/30/19990630BIT00510/bit0001.doc http://www.bit.se/bitonline/1999/06/30/

Astrazeneca launches 'Casodex'

ASTRAZENECA LAUNCHES 'CASODEX' 150 MG MONOTHERAPY IN THE UK FOR TREATMENT OF PROSTATE CANCER AstraZeneca today announced the first European product launch for the new company. 'Casodex' 150 mg, a single daily tablet for the treatment of prostate cancer, is now available in the UK, the first market world-wide in which this new presentation has been introduced. It is indicated for the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable. Further launches are

Generic challenge to Losec withdrawn i Canada

® GENERIC CHALLENGE TO LOSEC WITHDRAWN IN CANADA The patent protection for omeprazole, the active substance in Losec, expires in Canada in July 1999. However, due to national patent legislation, in Canada the opportunity for generic competition to Losec has existed since 1996 through compulsory licensing under AstraZeneca's substance patent. AstraZeneca has several other patents approved in Canada, including a formulation patent. For several years, various companies have sought to market generic omeprazole. AstraZeneca has successfully asserted its rights, and no generic product has reached

Close of AstraZeneca merger offers

CLOSE OF ASTRAZENECA MERGER OFFERS - ACCEPTANCES RECEIVED FROM SHAREHOLDERS REPRESENTING OVER 99.6% OF THE SHARES IN ASTRA st AstraZeneca announces that by 21 May 1999, the closing date of the Merger Offers, it has received acceptances from Astra shareholders representing in total 99.6 per cent of Astra's shares and 99.7 per cent of the voting rights attaching to Astra's shares. 1,545,714 new AstraZeneca shares will be issued to those Astra shareholders who have accepted the Merger Offers by 21 May 1999. As previously announced, the compulsory acquisition procedure has been initiated to

AstraZeneca 1999 AGM Trading Statement

AstraZeneca 1999 AGM Trading Statement* AstraZeneca: off to a firm start First quarter Pharmaceutical sales grew by 18% (17% at constant currency) with this trend being broadly maintained in April. Sales growth in the USA was 18%, in Europe 20% (17% at constant currency) and in Japan 14% (5% at constant currency). GI sales increased by 24% (24% at constant currency). Losec sales in the first quarter remained strong with growth of 24% (24% at constant currency). The rate of growth slowed slightly during April. Following March's price increase in the USA, a smoother pattern of sales is

AstraZeneca sells specialty chemicals business

ASTRAZENECA SELLS SPECIALTY CHEMICALS BUSINESS IN $2.1 BILLION (£1.3 BN) DEAL AstraZeneca today announced it has agreed to sell Zeneca Specialties for a cash amount of $2.1 billion (£1.3 bn) in a buyout jointly financed by Cinven and Investcorp. In 1998, the Zeneca Specialties businesses now being sold had sales of $1.1 bn (£686m), a net asset value of $765m (£460m) and operating profits of $150m (£90m). The transaction involves the worldwide business of Zeneca Specialties, including Resins and Novacote, and is expected to be completed by the end of June when all employees will transfer.

AstraZeneca intends to appeal following review of patent rulin in Australia

ASTRAZENECA INTENDS TO APPEAL FOLLOWING REVIEW OF PATENT RULING IN AUSTRALIA AstraZeneca intends to appeal a patent ruling pertaining to omeprazole (Losec®) handed down today by The Federal Court of Australia in Sydney in a dispute with the generic company Alphapharm Pty Ltd. The court clearly established, that under Australian patent law, the formulation used by Alphapharm in its generic omeprazole version infringed AstraZeneca's patented formulation technology. However, the court declared, that under Australian patent law, AstraZeneca's formulation patent was invalid. "We will be

Astra files suit against German generic company

ASTRA FILES SUIT AGAINST GERMAN GENERIC COMPANY Astra has filed suit in Germany against the German generic company Ratiopharm GmbH. The company recently launched a generic capsule version of omeprazole in Germany. Omeprazole is the substance used in Losec®. Astra maintains that Ratiopharm's action infringes Astra's formulation patent, which expires in 2007. In addition, Ratiopharm's action infringes Astra's Supplementary Protection Certificate (SPC)1 for the substance patent. Sales of Losec in Germany amounted to approximately USD 185 M. in 1998, corresponding to approximately 4 per cent of

Astra files lawsuit against German generic company

Södertälje, Sweden, May 5, 1999 ASTRA FILES SUIT AGAINST GERMAN GENERIC COMPANY Astra has filed suit in Germany against the German generic company Azupharma. The company recently launched a generic capsule version of omeprazole in Germany. Omeprazole is the substance used in Losec®. Astra maintains that Azupharma's action infringes Astra's formulation patent, which expires in 2007. In addition, Azupharma's action infringes Astra's Supplementary Protection Certificate (SPC)1 for the substance patent. "We will strongly assert our patent rights pertaining to omeprazole. The research and

Merger Offers Acceptances - Over 99 per cent

MERGER OFFERS ACCEPTANCES - OVER 99 PER CENT AstraZeneca announces that it has now received in total acceptances of the Merger Offers from Astra shareholders representing 99.4 per cent of Astra's shares and 99.5 per cent of the voting rights attaching to Astra's shares. Dr Tom McKillop, Chief Executive of AstraZeneca said, "This is a superb achievement. The high level of acceptances further endorses the overwhelming support for the Merger and the creation of AstraZeneca as a real force in world pharmaceuticals." By 3.00 pm (Stockholm time) on 23 April 1999, further valid acceptances of the

Merger Offers for Astra AB

AstraZeneca PLC: MERGER OFFERS FOR ASTRA AB As previously announced, the extended acceptance period relating to AstraZeneca's Merger Offers for the shares in Astra AB will close at 3.00 pm rd (Stockholm time) (9.00 am New York time) today, 23 April 1999. The Astra Class A shares and Class B shares will be delisted from the Stockholm Stock th Exchange and the London Stock Exchange from and including Monday 26 April 1999. An announcement will be made as to the level of acceptance received during th this extended acceptance period on 30 April 1999. New AstraZeneca shares will be issued to

Prilosec Q1 99

Södertälje, Sweden, April 22, 1999 @ @ SALES OF PRILOSEC (LOSEC ) IN THE U.S. UP 23 PERCENT DURING FIRST QUARTER OF 1999 Total sales of Prilosec (Losec) in the U.S. during the period January - March 1999 amounted to USD 895 m. (1998: 730 m.), an increase of 23 percent. Growth in total prescriptions February year-to-date was approximately 20 percent. Further Enquiries: Media: Mikael Widell, tel +46 8 553 264 28, Steve Brown, tel +44 171 304 5033 +46 70 311 99 60 Rachel Bloom, tel +1 302 886 7858 Investor Relations: Michael Olsson, tel +46 8 553 259 52 Elizabeth Sutton, tel +44 171 304 5101

Astra and Astra Pharmaceuticals file lawsuit against Cheminor

ASTRA AB AND ASTRA PHARMACEUTICALS, L.P. (APLP) FILE LAWSUIT AGAINST CHEMINOR DRUGS, LTD AND REDDY CHEMINOR INC. Astra AB and Astra Pharmaceuticals, L.P. (APLP) filed a lawsuit yesterday in New Jersey against Cheminor Drugs, Ltd. and Reddy Cheminor Inc. for patent infringement. The lawsuit is a result of an Abbreviated New Drug Application (ANDA) filed by Reddy Cheminor Inc. with the FDA concerning its intent to market a generic omeprazole product in the US. The antisecretory drug omeprazole is marketed in the US by APLP under the brand name Prilosec® and is marketed internationally by

Compulsory Acquisition of Astra AB Shares

AstraZeneca PLC: COMPULSORY ACQUISITION OF ASTRA AB SHARES AstraZeneca PLC announces that the compulsory acquisition procedure has been initiated through its wholly owned subsidiary Zeneca Holding AB to acquire for cash those Astra shares, including shares underlying Astra ADSs, not tendered under the Merger Offers. Zeneca Holding AB owns, including subsidiary holdings, 96.2 percent of the total Astra shares representing 96.4 percent of the total voting rights attaching to Astra shares. The Merger Offers may be accepted until 3.00 pm (Stockholm time) (9.00 am New York time) on Friday 23

Delisting of Astra AB

DELISTING OF ASTRA AB AstraZeneca PLC announces that Astra AB intends to apply for delisting of Astra A and B shares on the Stockholm and London Stock Exchanges with effect from Monday 26 April 1999. The last day for trading in the Astra shares on the Stockholm and London Stock Exchanges is expected to be Friday 23 April, 1999. Trading in the Astra A ADSs on the New York Stock Exchange is expected to be suspended from and including 23 April 1999, with such ADSs being delisted approximately 20 days thereafter. Trading in the Astra B ADSs was suspended on 6 April 1999 and an application will

Report from Astra's 1999 Annual General Meeting

REPORT FROM ASTRA'S 1999 ANNUAL GENERAL MEETING Since it was announced earlier today that the merger between Astra and Zeneca has been completed and the new company AstraZeneca PLC has been formed, this was Astra AB's final annual general meeting as a listed company. Astra's Annual General Meeting held on April 6 was attended by 1,277 stockholders, representing 41.7 percent of the total number of shares and 43.2 percent of the total number of voting rights. The Board's dividend proposal was approved by the Meeting. All Astra shareholders who have validly accepted the Merger Offers by the

Proposed Members of the Board of Astra AB

PROPOSED MEMBERS OF THE BOARD OF ASTRA AB As announced earlier today, the merger between Astra AB and Zeneca Group PLC has been completed. As also announced previously, the Board of AstraZeneca PLC was appointed on February 18, 1999, and will be made up as follows: Percy Barnevik - Non-Executive Chairman Sir David Barnes - Executive Deputy Chairman Håkan Mogren - Executive Deputy Chairman Tom McKillop - Chief Executive Jonathan Symonds - Executive Director, Chief Financial Officer Åke Stavling - Executive Director, Business Development & Integration Claes Wilhelmsson - Executive Director, R&

Merger Offers Declared Unconditional

MERGER OFFERS DECLARED UNCONDITIONAL Astra and Zeneca announce that all the conditions to the Merger Offers made by Zeneca for the issued share capital of Astra have been satisfied and that the Merger Offers are unconditional. The Merger has now been completed. By 3.00 pm (Stockholm time) (9.00 am New York time) on 30 March 1999, being the end of the initial acceptance period under the Merger Offers, valid acceptances of the Merger Offers had been received in respect of 1,289,503,363 Astra A Shares and 290,644,247 Astra B Shares, representing in aggregate 96.2 % of the total Astra Shares

AstraZeneca merger - closing timetable etc

ASTRAZENECA MERGER - CLOSING TIMETABLE AND REVISED DIVIDEND PAYMENT DATES Astra AB and Zeneca Group PLC announce that, as a result of the US anti-trust approval announced earlier today, they are able to provide further details of certain aspects of the closing timetable of the proposed merger. US anti-trust approval fulfils the only remaining regulatory consent required to effect the proposed merger. Closing Timetable As announced on 16 March 1999, the initial acceptance period for the Merger Offers made by Zeneca for all the issued share capital of Astra AB will close th on Tuesday 30

There are no items matching the current filter
There are no more items matching the current filter
Back to top